HCPCS G0283 is officially defined as "Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care." HCPCS G0283 is referenced in 23 tracked payer policy changes from Anthem BCBS, Health Net, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0283 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Effective January 1, 2027, HealthKeepers, Inc. (Anthem HealthKeepers Plus Medicaid in Virginia) will discontinue reimbursement for 44 specific procedure codes to align with the Virginia Department of Medical Assistance Services (DMAS) fee schedule. The practice must stop billing these codes for dates of service on or after that date, as claims for discontinued codes will be denied or subject to adjustment and recovery.
Health Net California is updating prior authorization requirements effective December 1, 2025, removing PA requirements for many DME items, prosthetics, sleep studies, varicose vein treatments, and therapy services while maintaining PA requirements for non-emergency air transport, hysterectomies, and skin substitutes. These changes aim to reduce administrative burden and streamline approval processes.
Humana's Medicare Advantage Outpatient Rehabilitation (Skilled Therapy) policy HUM-1186-011 was revised with an effective date of 11/05/2026, and its Change Summary logs a "CMS document update required" entry on that date, along with a 10/01/2026 coverage change. The revision updates the related CMS LCD/LCA references and coding information for PT/OT and related modalities, including high power laser therapy (97039, 97139), which the policy states will not be considered reasonable and necessary. Billing teams should confirm current coverage for the listed codes against the revised policy text and the cited MAC LCDs for their jurisdiction.
Effective June 1, 2026, Blue Shield of California updated the physical therapy policy statement, guidelines and literature. Rehabilitative PT is medically necessary when a qualified physical therapist is needed, the condition has the potential to improve in a reasonable and predictable period of time, and the documentation objectively verifies progressive functional improvement with quantifiable and attainable goals. Once a maintenance program is designed, coverage is not medically necessary when the patient can generally perform it alone or with family, a caregiver, or unskilled personnel, and evaluation and management codes 99201 through 99499 are not separately billable by physical therapists in independent practice.
Excellus policy 1.01.61 is a new policy with an effective date of 05/21/26, derived from policy 1.01.55, and it sets medical necessity criteria for TENS devices, including FDA approval, use for pain, symptoms lasting more than three months, failure of physical therapy, osteopathic manipulative therapy or chiropractic therapy, failure of medications, and a 30-day trial that has demonstrated efficacy. TENS is considered not medically necessary for labor and vaginal delivery pain, headaches and migraines, visceral abdominal pain, TMJ disorder, cancer pain, essential tremor, low back pain and neck pain. The policy also covers NMES for disuse muscle atrophy under listed criteria, considers FES for ambulation in spinal cord injury, stroke rehabilitation and gait training not medically necessary, and considers interferential stimulation, transcutaneous electrical joint stimulation for arthritis joint pain, and multiple modality delivery stimulation investigational.
Excellus BlueCross BlueShield policy 1.01.19 considers pelvic floor electrical stimulation (PFES) not medically necessary as a treatment for urinary or fecal incontinence. The policy states that published randomized controlled trials have reported inconsistent or inconclusive results. It also states that evidence is insufficient to determine the effectiveness of PFES for urinary or fecal incontinence, or to show that it is more effective than pelvic floor muscle exercises or sham simulation. This version is effective March 19, 2026, and its annual review kept the policy intent unchanged.
Aetna updated its policy on transcutaneous electrical acupoint stimulation (TEAS) devices, establishing that prescription ReliefBand and PrimaBella are NOW COVERED for post-operative nausea, chemotherapy-induced nausea unresponsive to antiemetics, and hyperemesis gravidarum unresponsive to conservative therapy. Over-the-counter ReliefBand for motion sickness remains non-covered. Extensive list of other TEAS indications are classified as experimental/investigational and not covered.
Aetna's Clinical Policy Bulletin 0625 on dysphagia therapy states which treatments it considers medically necessary and which it considers experimental, investigational, or unproven. Speech therapy for dysphagia, esophageal dilation for symptomatic obstruction of the esophagus, and non-biodegradable, non-drug eluting stent placement for refractory malignant esophageal strictures are medically necessary when the member meets the policy's criteria. Acupuncture, electrical stimulation, transcranial direct current stimulation, hyperbaric oxygen therapy for radiation-induced dysphagia and several other interventions are listed as experimental, investigational, or unproven.
Aetna's Clinical Policy Bulletin 0729 sets the medical necessity rules for selected treatments of diabetic neuropathy. Percutaneous electrical stimulation is considered medically necessary for members who failed to adequately respond to conventional treatments, but use for more than 4 weeks is considered not medically necessary, and dorsal column stimulation is medically necessary for members who meet the criteria in CPB 0194 - Spinal Cord Stimulation. The bulletin lists many other interventions, including acupuncture, dorsal root ganglion stimulation, peripheral nerve blocks and tumor necrosis factor-alpha inhibitors, as experimental, investigational, or unproven for this indication.
Aetna considers constraint-induced movement therapy (CIMT) medically necessary for upper limb hemiparesis in persons with stroke who have at least 10 degrees of active wrist and finger extension and no sensory or cognitive deficits, and for upper limb hemiparesis in hemiplegic cerebral palsy. Coverage is for a 4-week CIMT program that can be extended by another 4 weeks when documentation shows improvement of functions. CIMT for lower limb hemiparesis, brachial plexus palsy, multiple sclerosis, Parkinson's disease, spinal cord injury, traumatic brain injury and hemiplegia from brain tumors, along with several CIMT combinations and related therapies, are considered experimental, investigational or unproven.
Aetna covers alternative medicine interventions when they are supported by adequate evidence of safety and effectiveness in the peer-reviewed published medical literature, subject to benefit plan limitations and exclusions. Acupuncture, biofeedback, chelation therapy, chiropractic services and electrical stimulation are addressed under separate Aetna policies. Many other interventions are listed as experimental, investigational or unproven, including intravenous micronutrient therapy (Myers' Cocktail), Gua Sha, colon hydrotherapy and the Patricia Kane protocol, and standard benefit plans exclude nutritional supplements and medical marijuana.
Aetna considers constraint-induced movement therapy (CIMT) medically necessary for upper limb hemiparesis in persons with stroke who have at least 10 degrees of active wrist and finger extension and no sensory and cognitive deficits, and for upper limb hemiparesis in hemiplegic cerebral palsy. Coverage is for a 4-week CIMT program that can be extended for another 4 weeks if there is documentation of improvement of functions. CIMT for brachial plexus palsy, hemiplegia from brain tumors, lower limb hemiparesis in stroke, multiple sclerosis, Parkinson's disease, spinal cord injury and traumatic brain injury, and CIMT combined with peripheral nerve stimulation, transcranial stimulation, biofeedback or electroacupuncture, are considered experimental, investigational or unproven.
Aetna considers electrical stimulation for chronic ulcers medically necessary durable medical equipment for arterial ulcers, diabetic ulcers, Stage III or IV pressure ulcers, and venous stasis ulcers when it is used as adjunctive therapy after there are no measurable signs of healing for at least 30 days of conventional wound treatment. A course of treatment is not typically expected to exceed 60 minutes per day or a total of more than 4 weeks, and continued stimulation is not medically necessary if measurable signs of healing are not demonstrated within a 4-week treatment period. Electrical stimulation for chronic ulcers in the home setting is considered not medically appropriate, and it is considered experimental, investigational, or unproven for uses such as prevention of ulcers and pressure sores, treatment of infected wounds, and microcurrent as an adjunctive therapy to enhance chronic wound healing.
Aetna Clinical Policy Bulletin 0625 addresses dysphagia therapy and sets the criteria for speech therapy, esophageal dilation and stent placement. Speech therapy for dysphagia is considered medically necessary, regardless of the presence of a communication disability, when the member has weight loss or malnutrition from dysphagia and cannot obtain adequate nutrition orally, has a history of or high risk for recurrent aspirations or choking, or is unable to swallow and has a nasogastric or gastrotomy tube for nutrition. Esophageal dilation for symptomatic obstruction of the esophagus and non-biodegradable, non-drug eluting stent placement for refractory malignant esophageal strictures are also considered medically necessary, while many other treatments such as acupuncture, electrical stimulation, mirror therapy and transcranial stimulation are considered experimental, investigational or unproven because their effectiveness has not been established.
Aetna considers the Ilizarov method for distraction osteosynthesis medically necessary for members with an angular or rotational deformity of a long bone, a bone defect, or a limb length discrepancy who also meet one of the listed selection criteria, such as a leg length discrepancy of more than 4 cm, an arm length discrepancy of more than 5 cm, or a long bone fracture not healed in 6 or more months after electrical stimulation and bone grafting have failed. The PRECICE intramedullary limb lengthening system is considered medically necessary for lengthening the tibia and femur in persons with a leg length discrepancy of more than 4 cm. Ilizarov use for other indications, the intramedullary skeletal kinetic distractor, pulsed ultrasound as an adjuvant therapy, and Phenix nails are considered experimental, investigational or unproven, and Ilizarov use to correct short stature is considered cosmetic.
Aetna considers percutaneous electrical stimulation medically necessary for diabetic neuropathy only for members who did not respond adequately to conventional treatments, including anti-convulsants (especially pregabalin), anti-depressants (such as amitriptyline and duloxetine), and other agents such as capsaicin and isosorbide dinitrate spray. Use of percutaneous electrical stimulation for more than 4 weeks for diabetic neuropathy is considered not medically necessary. Dorsal column stimulation is considered medically necessary for members with diabetic peripheral neuropathy who meet the criteria in CPB 0194 (Spinal Cord Stimulation), while acupuncture, dorsal root ganglion stimulation, ozone therapy, peripheral nerve blocks and low-level laser therapy are considered experimental, investigational, or unproven for diabetic neuropathy because their clinical value for this indication has not been established.
High frequency pulsed electromagnetic stimulation, also called therapeutic magnetic resonance, is considered experimental, investigational or unproven for all indications listed, including acute post-operative pain and edema, bone consolidation, cancer, chronic low back pain, osteoarthritis, osteoporosis, Parkinson's disease, soft tissue injuries, tendinopathy and wounds. Transcutaneous low frequency pulsed electromagnetic stimulation is considered experimental, investigational or unproven for chronic pain including low back pain, fibromyalgia, hand tremors in Parkinson's disease, osteoarthritis, multiple sclerosis spasticity, neuropathic pain and wounds. CPT 0766T and 0767T, and HCPCS E0761, G0295 and G0329, are listed as not covered for the indications in the policy, and intermittent pulsed electromagnetic stimulation for fracture healing is addressed in CPB 0343 Bone Growth Stimulators.
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Aetna considers dynamic MRI in persons with complex organ prolapse to supplement the physical examination, laparoscopic suture rectopexy for rectal prolapse, Le Fort colpocleisis for severe utero-vaginal prolapse in elderly and chronically ill persons who no longer desire coital function, sacrocolpopexy for vaginal apical prolapse repair, and tension-free vaginal tape for pelvic organ prolapse complicated by stress urinary incontinence medically necessary. Aetna considers biodegradable cog threads, biologic grafts for vaginal apical prolapse, combined laparoscopic-vaginal lateral suspension, pectopexy, laser therapy, transcutaneous electrical nerve stimulation, trans-vaginal absorbable meshes or biological grafts, vNOTES presacral-uterosacral hysteropexy, vNOTES uterosacral ligament suspension, vaginal tactile imaging, and genetic testing experimental, investigational, or unproven for pelvic organ prolapse. The covered CPT codes apply when the selection criteria are met, and specific CPT, HCPCS and ICD-10 codes are listed as not covered for the indications in the policy.
Interferential current stimulation is considered investigational under this policy. The policy lists CPT 20974, 97014 and 97032 and HCPCS E0745, E1399, G0283, S8130 and S8131 as investigational codes. The policy description was updated on 09/18/2026 regarding interferential current stimulation and devices, and the policy statement is unchanged.
Electrical or magnetic stimulation of the pelvic floor muscles (pelvic floor stimulation) is considered investigational as a treatment for urinary incontinence. Pelvic floor stimulation is also considered investigational as a treatment for fecal incontinence. Investigational services are not considered medically necessary. Under the Federal Employee Program, FDA-approved devices, drugs or biologics may not be considered investigational and may be assessed only on the basis of their medical necessity.
Aetna clinical policy bulletin 0676 (reviewed October 7, 2026) covers prescription ReliefBand and PrimaBella devices for post-operative or chemotherapy-induced nausea that does not respond to antiemetics and conservative care, and for hyperemesis gravidarum that does not respond to conservative therapy. It treats other transcutaneous acupoint stimulation uses, such as motion sickness, autism, dysmenorrhea and fertility, as experimental, and does not cover over-the-counter disposable ReliefBand devices. The source gives a review date but no effective date.
This is a reissue with no substantive changes to Independence Blue Cross Commercial Policy 10.03.01o on Outpatient Physical Medicine, Rehabilitation, and Habilitation Services. The policy was last reviewed and reissued on 09/18/2026 per the company's annual review process. Key coverage requirements, modifier mandates (GO for OT, GP for PT), experimental/investigational exclusions (including LLLT and CPT 97037), and state mandate considerations for Autism Spectrum Disorders remain unchanged.
Watch G0283
Get one email when a payer policy names G0283, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for G0283
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for G0283 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.